Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that it will release the results of the Phase IIa clinical trial for high blood pressure (QGC001 program) on September 29, 2016, after the close of Euronext Paris
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2016/09/QUANTUM_PR_QGC001-results-agenda_20160912_VF_EN.pdf” target=”_blank” title=”Download Press Release” size=”small” color=”red”]
